Premium
Centchroman—a non‐steroidal anti‐cancer agent for advanced breast cancer: Phase‐II study
Author(s) -
Misra N. C.,
Nigam P. K.,
Gupta Ruby,
Agarwal A. K.,
Kamboj V. P.
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430506
Subject(s) - medicine , breast cancer , lymph node , cancer , oncology , metastatic breast cancer , complete response , lymph , gastroenterology , chemotherapy , pathology
Treatment with Centchroman (3,4‐trans‐2,2‐dimethyl‐3‐phenyl‐4‐p‐(βpyrrolidinoethoxy) phenyl‐7‐methoxy chroman) has been evaluated in 4 male and 75 female patients with advanced breast cancer. The overall response rate, including both male and female cases, was 40.5%. Among the female patients, the overall response rate was 38.7%. The median duration of response was 6 months. One of the 4 male patients showed a complete response and 2 showed partial responses. The responses were more marked for bone, pulmonary, soft tissue, skin and lymph‐node metastases than for liver metastases.